Trial
NCT02131506
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Collaborators
—
Condition
HER-2 Positive Breast Cancer
Intervention
Lapatinib, Caelyx
Why stopped
Safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-02